Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas.
Bruton’s tyrosine kinase inhibitor
CAR-T cell therapy
immune checkpoint inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Mar 2023
27 Mar 2023
Historique:
received:
24
01
2023
revised:
20
03
2023
accepted:
23
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Infections are well known complications of some targeted drugs used to treat solid organ cancer and hematological malignancies. Furthermore, Individual patient risk factors are associated with underlying pathologies, concomitant immunosuppressive treatment, prior treatment and use of anti-infective prophylaxis. Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. In this narrative review, we present the current state of knowledge concerning the infectious complications occurring in patients treated with immune checkpoint inhibitors (ICIs), Bruton's tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, antiapoptotic protein BCL-2 inhibitors, Janus kinase inhibitors or CAR-T cell infusion. We searched for studies treating infectious complications of ICIs, BTK inhibitors, PI3K inhibitors, antiapoptotic protein BCL-2 inhibitors and CAR-T cell therapy. We included randomized, observational studies and case reports. Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. Treatment of irAEs with corticosteroids and other immunosuppressive agents can lead to opportunistic infections. Bruton's tyrosine kinase (BTK) inhibitors are associated with higher rate of infections, including invasive fungal infections. Infections, particularly fungal ones, are common in patients treated with BTK inhibitors even though most of the complications occurring among patients treated by ICIs or CART-cells infusion are associated with the treatment of side effects related to the use of these new treatments. The diagnosis of these infectious complications can be difficult and may require extensive investigations.
Sections du résumé
BACKGROUND
BACKGROUND
Infections are well known complications of some targeted drugs used to treat solid organ cancer and hematological malignancies. Furthermore, Individual patient risk factors are associated with underlying pathologies, concomitant immunosuppressive treatment, prior treatment and use of anti-infective prophylaxis. Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs.
OBJECTIVES
OBJECTIVE
In this narrative review, we present the current state of knowledge concerning the infectious complications occurring in patients treated with immune checkpoint inhibitors (ICIs), Bruton's tyrosine kinase (BTK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, antiapoptotic protein BCL-2 inhibitors, Janus kinase inhibitors or CAR-T cell infusion.
SOURCES
METHODS
We searched for studies treating infectious complications of ICIs, BTK inhibitors, PI3K inhibitors, antiapoptotic protein BCL-2 inhibitors and CAR-T cell therapy. We included randomized, observational studies and case reports.
CONTENT
BACKGROUND
Immune-related adverse events (irAEs) are frequent among patients treated with new targeted drugs. Treatment of irAEs with corticosteroids and other immunosuppressive agents can lead to opportunistic infections. Bruton's tyrosine kinase (BTK) inhibitors are associated with higher rate of infections, including invasive fungal infections.
IMPLICATIONS
CONCLUSIONS
Infections, particularly fungal ones, are common in patients treated with BTK inhibitors even though most of the complications occurring among patients treated by ICIs or CART-cells infusion are associated with the treatment of side effects related to the use of these new treatments. The diagnosis of these infectious complications can be difficult and may require extensive investigations.
Identifiants
pubmed: 37046650
pii: cancers15071989
doi: 10.3390/cancers15071989
pmc: PMC10093532
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Emerg Infect Dis. 2018 Aug;24(8):1594-1596
pubmed: 30016251
Ann Intensive Care. 2021 Dec 24;11(1):182
pubmed: 34951668
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Leuk Lymphoma. 2015;56(10):2779-86
pubmed: 25726955
J Immunother Cancer. 2014 Jun 18;2:19
pubmed: 24991413
Cancer Med. 2021 Nov;10(21):7629-7640
pubmed: 34558211
Blood. 2018 Nov 1;132(18):1985-1988
pubmed: 30021784
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Haematologica. 2021 Apr 01;106(4):978-986
pubmed: 32327504
Am J Hematol. 2019 Dec;94(12):1325-1334
pubmed: 31490009
Curr Fungal Infect Rep. 2019 Sep;13(3):86-98
pubmed: 31555394
Mycopathologia. 2019 Feb;184(1):181-185
pubmed: 30101407
J Adv Pract Oncol. 2016 Sep-Oct;7(6):604-613
pubmed: 29588866
Clin Cancer Res. 2018 Sep 15;24(18):4371-4379
pubmed: 29895707
Clin Infect Dis. 2016 Dec 1;63(11):1490-1493
pubmed: 27501841
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Blood. 2016 Jul 21;128(3):331-6
pubmed: 27252232
Transplant Cell Ther. 2021 Dec;27(12):973-987
pubmed: 34587552
Ann Oncol. 2010 Aug;21(8):1712-1717
pubmed: 20147741
J Clin Oncol. 2015 Jun 10;33(17):1889-94
pubmed: 25667295
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S53-S70
pubmed: 29454849
Arthritis Res Ther. 2019 Apr 5;21(1):89
pubmed: 30953540
J Immunother. 2021 Nov-Dec 01;44(9):351-354
pubmed: 34369454
Eur J Haematol. 2018 Apr;100(4):325-334
pubmed: 29285806
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33020237
Hematol Oncol. 2019 Feb;37(1):3-14
pubmed: 30187496
Open Forum Infect Dis. 2017 Feb 09;4(1):ofw261
pubmed: 28480254
JAMA Oncol. 2020 Oct 1;6(10):1529-1530
pubmed: 32433719
Thorac Cancer. 2020 Jun;11(6):1689-1694
pubmed: 32311221
Lancet Infect Dis. 2019 Jun;19(6):e188-e199
pubmed: 30744964
Ann Intensive Care. 2019 Feb 1;9(1):25
pubmed: 30707321
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
Blood Cancer J. 2021 Oct 18;11(10):168
pubmed: 34663791
Blood Adv. 2021 Jan 12;5(1):143-155
pubmed: 33570626
ACG Case Rep J. 2021 Nov 24;8(11):e00701
pubmed: 34841000
J Hematol Oncol. 2020 Jan 3;13(1):1
pubmed: 31900191
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321
pubmed: 31446199
Leuk Lymphoma. 2019 Jun;60(6):1572-1575
pubmed: 30632838
Cancer Immunol Res. 2016 Mar;4(3):194-203
pubmed: 26787823
Oncotarget. 2018 Jan 22;9(16):13023-13035
pubmed: 29560128
Clin Infect Dis. 2021 Aug 2;73(3):e815-e821
pubmed: 33507235
Haematologica. 2017 Oct;102(10):e397-e399
pubmed: 28659336
Blood Adv. 2022 Apr 12;6(7):2427-2433
pubmed: 34749396
Br J Haematol. 2021 Jul;194(1):69-77
pubmed: 34121184
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Eur J Cancer. 2019 Mar;109:172-174
pubmed: 30731278
Bone Marrow Transplant. 2019 Nov;54(11):1868-1880
pubmed: 31092900
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Leuk Lymphoma. 2021 Jul;62(7):1692-1701
pubmed: 33563059
Case Rep Gastroenterol. 2020 Feb 25;14(1):103-109
pubmed: 32231510
Leuk Lymphoma. 2017 Dec;58(12):2981-2982
pubmed: 28554246
BMC Infect Dis. 2021 Jan 28;21(1):121
pubmed: 33509115
Blood Adv. 2022 Feb 22;6(4):1296-1308
pubmed: 34724705
J Pediatr Hematol Oncol. 2021 Mar 1;43(2):e163-e164
pubmed: 32097278
Lancet Oncol. 2017 Jan;18(1):88-99
pubmed: 27916398
Arthritis Rheumatol. 2014 Nov;66(11):2924-37
pubmed: 25047021
Ann Oncol. 2021 Jan;32(1):34-48
pubmed: 33098993
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Clin Infect Dis. 2018 Aug 1;67(4):533-540
pubmed: 29481659
Blood. 2018 Jan 4;131(1):121-130
pubmed: 29038338
Bone Marrow Transplant. 2020 Dec;55(12):2347-2349
pubmed: 32719501
J Oncol Pharm Pract. 2019 Apr;25(3):710-714
pubmed: 29343153
Curr Opin Infect Dis. 2020 Dec;33(6):449-457
pubmed: 33009139
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Cell Res. 2017 Jan;27(1):38-58
pubmed: 28025979
Drugs. 2018 Nov;78(16):1653-1663
pubmed: 30390220
Mycoses. 2020 Aug;63(8):787-793
pubmed: 32458510
Cell Commun Signal. 2022 Apr 7;20(1):44
pubmed: 35392976
Clin Cancer Res. 2017 Mar 1;23(5):1149-1155
pubmed: 28073846
Expert Opin Drug Saf. 2020 Nov;19(11):1377-1393
pubmed: 32946324
Sci Rep. 2022 May 3;12(1):7140
pubmed: 35504889
Front Immunol. 2023 Jan 04;13:1070660
pubmed: 36685572
Oncoimmunology. 2015 May 27;4(10):e1040218
pubmed: 26451305
Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766
pubmed: 30982883
J Infect. 2020 Feb;80(2):232-254
pubmed: 31705917
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Cancer Cell. 2022 Jun 13;40(6):590-591
pubmed: 35598602
Eur J Haematol. 2022 May;108(5):359-368
pubmed: 35100451
Leuk Lymphoma. 2022 Apr;63(4):1001-1004
pubmed: 34842037
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Eur J Neurol. 2021 Nov;28(11):3814-3819
pubmed: 34251719
Clin Infect Dis. 2009 Jun 15;48(12):1695-703
pubmed: 19441981
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Leukemia. 2021 Dec;35(12):3585-3588
pubmed: 34750508
Clin Infect Dis. 2018 Aug 16;67(5):687-692
pubmed: 29509845
BMJ Case Rep. 2020 Apr 29;13(4):
pubmed: 32354764
Haematologica. 2019 May;104(5):e211-e214
pubmed: 30442728
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Clin Infect Dis. 2018 Jan 6;66(1):140-148
pubmed: 29029010
Blood Cancer J. 2020 Aug 5;10(8):79
pubmed: 32759935
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Cancer Med. 2022 Jan;11(1):21-27
pubmed: 34873868
Open Forum Infect Dis. 2020 Apr 09;7(5):ofaa126
pubmed: 32391404
Respirol Case Rep. 2020 May 10;8(5):e00580
pubmed: 32399215
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Ther Adv Hematol. 2022 Jun 16;13:20406207221101697
pubmed: 35747462
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Case Rep Oncol Med. 2019 Aug 27;2019:2178925
pubmed: 31534809
Nat Rev Clin Oncol. 2013 May;10(5):267-76
pubmed: 23546520
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Infection. 2021 Apr;49(2):215-231
pubmed: 32979154
J Natl Compr Canc Netw. 2012 Nov 1;10(11):1412-45
pubmed: 23138169
Clin Lung Cancer. 2019 May;20(3):e247-e250
pubmed: 30635258
Br J Haematol. 2017 Apr;177(2):243-253
pubmed: 28220479
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358